Plain-English translation of NCT05263830 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is studying whether a protein called glypican-3 can help doctors predict which patients with advanced liver cancer will benefit from newer immunotherapy drugs like Atezolizumab and Bevacizumab. Researchers will collect blood and tissue samples from about 240 patients receiving these treatments to see if glypican-3 levels can forecast how well the medication will work for each person.
Currently, doctors cannot easily predict which patients will respond well to immunotherapy for advanced liver cancer, which means some people may receive treatments that won't help them. This study aims to find a simple blood test marker that can identify patients most likely to benefit from the new treatment, so doctors can make better, more personalized treatment decisions.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the immunotherapy treatment your doctors already recommended (Atezolizumab with Bevacizumab, or another approved combination). Throughout your treatment, researchers will collect blood samples and review tissue samples to measure glypican-3 levels and other markers. These samples help doctors understand whether the protein levels can predict how well the treatment works for you. The study follows you during your standard cancer care appointments.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
France